The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
RNA Display Methods for the Discovery of Bioactive Macrocycles
Abstract
The past two decades have witnessed the emergence of macrocycles, including macrocyclic peptides, as a promising yet underexploited class of de novo drug candidates. Both rational/computational design and in vitro display systems have contributed tremendously to the development of cyclic peptide binders of either traditional targets such as cell-surface receptors and enzymes or challenging targets such as protein-protein interaction surfaces. mRNA display, a key platform technology for the discovery of cyclic peptide ligands, has become one of the leading strategies that can generate natural-product-like macrocyclic peptide binders with antibody-like affinities. On the basis of the original cell-free transcription/translation system, mRNA display is highly evolvable to realize its full potential by applying genetic reprogramming and chemical/enzymatic modifications. In addition, mRNA display also allows the follow-up hit-to-lead development using high-throughput focused affinity maturation. Finally, mRNA-displayed peptides can be readily engineered to create chemical conjugates based on known small molecules or biologics. This review covers the birth and growth of mRNA display and discusses the above features of mRNA display with success stories and future perspectives and is up to date as of August 2018.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
Iqbal, E. S., Dods, K. K., & Hartman, M. C. T. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02931d · Cited by 26
Flexizymes as a tRNA Acylation Tool Facilitating Genetic Code Reprogramming
Goto, Y., & Suga, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-545-9_29 · Cited by 22
Self-citationtRNA engineering for manipulating genetic code
Katoh, T., Iwane, Y., & Suga, H. (2018) · RNA Biology · doi:10.1080/15476286.2017.1343227 · Cited by 22
Self-citationNishio, K., Belle, R., Katoh, T., Kawamura, A., Sengoku, T., Hanada, K., Ohsawa, N., Shirouzu, M., Yokoyama, S., & Suga, H. (2018) · ChemBioChem · doi:10.1002/cbic.201800047 · Cited by 22
Self-citationFlexizymes, Their Evolutionary History and Diverse Utilities
Passioura, T., & Suga, H. (2013) · Topics in current chemistry · doi:10.1007/128_2013_421 · Cited by 21
Self-citationMercaldi, G. F., Pereira, H. M., Cordeiro, A. T., et al. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08586.x · Cited by 21
Structure-activity studies of a macrocyclic peptide inhibitor of histone lysine demethylase 4A
Passioura, T., Bhushan, B., Tumber, A., Kawamura, A., & Suga, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.013 · Cited by 21
Self-citationFlexizyme as a versatile tRNA acylation catalyst and the application for translation
Murakami, H., Ohta, A., Goto, Y., Sako, Y., & Suga, H. (2006) · Nucleic Acids Symposium Series · doi:10.1093/nass/nrl018 · Cited by 20
Self-citationSuga, H. (2018) · Journal of Peptide Science · doi:10.1002/psc.3055 · Cited by 19
Self-citationBashiruddin, N. K., Matsunaga, Y., Nagano, M., Takagi, J., & Suga, H. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00219 · Cited by 19
Self-citationKumachi, S., Husimi, Y., & Nemoto, N. (2016) · ACS Omega · doi:10.1021/acsomega.6b00015 · Cited by 18
Flexizymes-facilitated Genetic Code Reprogramming Leading to the Discovery of Drug-like Peptides
Terasaka, N., & Suga, H. (2014) · Chemistry Letters · doi:10.1246/cl.130910 · Cited by 15
Self-citationHistorical review: Peptidyl transfer, the Monro era
Maden, B. E. H. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.008 · Cited by 11
In Vitro Selection Combined with Ribosomal Translation Containing Non-proteinogenic Amino Acids.
Fujino, T., & Murakami, H. (2016) · The chemical record · doi:10.1002/tcr.201500239 · Cited by 7
Crystallographic Analysis of MATE-Type Multidrug Exporter with Its Inhibitors
Kusakizako, T., Tanaka, Y., Hipolito, C. J., Suga, H., & Nureki, O. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7454-2_3 · Cited by 3
Self-citation
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
Cyclic Peptides for Drug Development
Ji, X., Nielsen, A. L., & Heinis, C. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202308251 · Cited by 411
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2021) · SLAS Discovery · doi:10.1177/2472555220965528 · Cited by 380
Huang, J., Xu, Y., Xue, Y., Huang, Y., Li, X., Chen, X., Xu, Y., Zhang, D., Zhang, P., Zhao, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00991-2 · Cited by 270
Self-citation
Metadata
- Authors
- Huang, Y., Wiedmann, M. M., & Suga, H.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-05
- Volume
- 119
- Issue
- 17
- Pages
- 10360-10391
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2900111464
- Cited by
- 298
- References
- 215
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.